Displaying 1281 - 1300 of 1557
Health Care and Competition Law and Policy Hearings
FTC/DOJ Release Agenda for Upcoming Sessions of Joint Health Care Hearings
FTC/DOJ Release Agenda for First Session of Health Care Hearings
FTC Staff Issues Advisory Opinion Regarding Proposed Formation of Physicians' Healthcare Advocacy Group in Dayton, Ohio
Baxter International Inc., and Wyeth, In the Matter of
Baxter settled Commission concerns stemming from its $316 million proposed acquisition of Wyeth Corporation's generic injectable drug business and agreed to divest several pharmaceutical products. The Commission charged that the acquisition would reduce competition in the manufacture and sale of propofol (a general anesthetic); new injectable iron replacement therapies; metocloprarnide (used to treat nausea); and vecuronium and pancuronium (neuromuscular blocking agents used to temporarily freeze muscles during surgery). The consent order requires divestitures in each of the pharmaceutical markets.
Announced Action for January 29, 2003
SmithKline Beecham Corp. v. Apotex Corp.
FTC/DOJ Hearings to Focus on Health Care And Competition Law and Policy
FTC Requires Divestitures in Connection with Baxter's Purchase of Wyeth's Generic Injectable Drug Business
Workshop on Deception in Weight Loss Advertising
FTC Releases Health Care and Competition Law and Policy Workshop Materials
FTC Chairman Announces Public Hearings on Health Care and Competition Law and Policy to Begin in February 2003
System Health Providers, Inc., and Genesis Physicians Group, Inc.
System Health Providers and its parent corporation, Genesis Physicians Group, Inc., settled charges that they collectively bargained with health insurance firms to accept proposed fee schedules; discouraged members from entering into contracts directly with payers; and refused to deal with health insurance firms and other third-party payers except on collectively agreed upon terms. The order prohibits the recurrence of the alleged practices and actions.
FTC Staff Opposes Ohio Bill To Allow Physician Collective Bargaining
Statement of Federal Trade Commission Chairman Timothy Muris on the FDA's Proposals to Improve Consumer Access To Lower-Cost Generic Drugs
Announced Actions for October 11, 2002
R.T. Welter and Associates, Inc.
Prepared Statement of the Federal Trade Commission On Competition in the U.S. Pharmaceutical Industry
Displaying 1281 - 1300 of 1557